WO2009041972A1 - Composés antibactériens et leurs procédés d'utilisation - Google Patents

Composés antibactériens et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2009041972A1
WO2009041972A1 PCT/US2007/079672 US2007079672W WO2009041972A1 WO 2009041972 A1 WO2009041972 A1 WO 2009041972A1 US 2007079672 W US2007079672 W US 2007079672W WO 2009041972 A1 WO2009041972 A1 WO 2009041972A1
Authority
WO
WIPO (PCT)
Prior art keywords
mhz
ppm
compound
mmol
cdcl
Prior art date
Application number
PCT/US2007/079672
Other languages
English (en)
Inventor
Shahriar Mobashery
Peter I. O'daniel
Mayland Chang
Original Assignee
University Of Notre Dame Du Lac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Notre Dame Du Lac filed Critical University Of Notre Dame Du Lac
Priority to PCT/US2007/079672 priority Critical patent/WO2009041972A1/fr
Publication of WO2009041972A1 publication Critical patent/WO2009041972A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Embodiments of the present invention relate to the field of chemistry and biochemistry, and, more specifically, to antibacterial compounds and methods of using antibacterial compounds. Background
  • Penicillin-binding proteins are a group of proteins characterized by their affinity for and binding of penicillin. PBPs do not just bind penicillin, but rather bind all beta-lactam antibiotics, which are a family of antibiotics sharing a four membered lactam ring. There are a large number of PBPs, usually several in each organism, and they are found mostly as membrane-bound proteins, but a few are known to be non-membrane associated. Different PBPs occur in different numbers per cell and have varied affinities for different kinds of ⁇ -lactam antibiotics. PBPs are involved in the final stages of the synthesis of peptidoglycan, which is the major component of bacterial cell walls.
  • Bacterial cell wall synthesis is essential to growth, cell division (thus reproduction), and maintenance of the cellular structure in bacteria. Inhibition of PBPs leads to irregularities in bacterial cell wall structure such as elongation, lesions, loss of selective permeability, and eventual cell death and lysis. Bacterial cell wall synthesis, and in particular PBPs, provides a good target for drugs of selective toxicity because the metabolic pathways and enzymes are unique to bacteria.
  • Figure 1 illustrates the minimum inhibitory concentration ( ⁇ g/mL) for two compounds tested against various strains of Staphylococcus aureus and Entercoccus in accordance with various embodiments of the present invention
  • FIGS. 2 and 3 illustrate the schemes for synthesis of various compounds in accordance with various embodiments of the present invention.
  • Figure 4 illustrates antibacterial compounds in accordance with various embodiments of the present invention in which the five-member ring is modified.
  • A/B means A or
  • a phrase in the form "A and/or B” means “(A), (B), or (A and B)".
  • a phrase in the form "at least one of A, B, and C” means “(A), (B), (C), (A and B), (A and C), (B and C), or (A, B and C)”.
  • a phrase in the form "(A)B” means "(B) or (AB)" that is, A is an optional element.
  • halogen refers to F, Cl, Br and I.
  • hydroxyl refers to a moiety containing one or more OH.
  • cyano refers to a moiety containing one or more -C ⁇ N.
  • alkyl refers to both straight- and branched-chain moieties.
  • alkynyl refers to both straight- and branched- chain moieties containing one or more -C ⁇ C-.
  • alkoxy refers to -O-alkyl groups.
  • aryloxy refers to -O-aryl groups.
  • cycloalkyl refers to a cyclic alkyl moiety. Unless otherwise stated cycloalkyl moieties include between 3 and 8 carbon atoms.
  • amino refers to NH 2 , NHR, or NR 2 .
  • R can be alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, het or aryl.
  • nitro refers to NO 2
  • phosphate refers to but is not limited to -O-P-
  • aryl refers to phenyl and naphthyl.
  • sulfhydryl refers to -SH.
  • het refers to a mono- or bi-cyclic ring system containing one or more heteroatom selected from O, S, and N. Each mono-cyclic ring may be aromatic, saturated or partially unsaturated.
  • a bi-cyclic ring system may include a mono-cyclic ring containing one or more heteroatom fused with a cycloalkyl or aryl group.
  • a bi-cyclic ring system may also include a mono-cyclic ring containing one or more heteroatom fused with another het, mono-cyclic ring system.
  • heterox examples include but are not limited to pyridine, thiophene, furan, pyrazoline, pyrrole, pyrazoline, pyrimidine, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 3-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 4-oxo-2-imidazolyl, 1 ,2,4-oxadiazole, 1 ,3,4-oxadiazole, 4-pyridazinyl, 3-pyrazinyl, 4-oxo-2-imidazolyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5- isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 4-oxazolyl, 4-ox
  • heteroaryl refers to a mono- or bicyclic het in which one or more cyclic ring is aromatic.
  • substituted heteroaryl refers to a heteroaryl moiety substituted with one or more functional groups selected from halogen, alkyl, hydroxyl, amino, alkoxy, cyano, and nitro.
  • Each Q 10 is independently selected from H, alkyl, cycloalkyl, het, cycloalkenyl, and aryl.
  • the het, cycloalkyl, cycloalkenyl, and aryl being optionally substituted with 1-3 substitutuents selected from halo and Q 13 .
  • Each Q 11 is independently selected from H, halogen, alkyl, aryl, cycloalkyl, and het.
  • Each Q14 is independently selected from H, alkyl, cycloalkyl, phenyl, or naphthyl, each optionally substituted with 1 -4 substituents independently selected from F, Cl, Br, I, -OQi 6 , -SQi 6 , -S(O) 2 Qi 6 , -S(O)Qi 6 , -OS(O) 2 Qi 6 , -NQi 6 Qi 6 , - C(O)Qi 6 , -C(S)Qi 6 , -C(O)OQi 6 , -NO 2 , -C(O)NQi 6 Qi 6 , -C(S)NQi 6 Qi 6 , -CN, - NQi 6 C(O)Qi 6 , -NQi 6 C(S)Qi 6 , -NQi 6 C(O)NQi 6 Qi 6 , -NQi 6 C(S)NQi 6
  • Each Q 16 is independently selected from H, alkyl, and cycloalkyl.
  • the alkyl and cycloalkyl optionally including 1 -3 halogens.
  • Embodiments of the present invention provide novel antibactehals.
  • antibactehals are provided that target penicillin-binding proteins (PBPs).
  • PBPs penicillin-binding proteins
  • the antibactehals provided herein may inhibit other biochemical processes of bacteria.
  • the antibactehals of this invention may have useful activity against a variety of organisms.
  • the in vitro activity of compounds of this invention may be assessed by standard testing procedures such as the determination of minimum inhibitory concentration (MIC) by agar dilution.
  • MIC minimum inhibitory concentration
  • the antibactehals described herein may be useful for sterilization, sanitation, antisepsis, and disinfection.
  • the antibactehals may be applied to a location in need of sterilization, sanitation, antisepsis, or disinfection, by methods known to those skilled in the art.
  • the antibbactehals may be incorporated into a cleaning solution that is applied, such as by spraying or pouring, to an item in need of sterilization, sanitation, antisepsis, or disinfection.
  • the antibactehals may be used alone or in combination.
  • the antibactehals may be applied in varying concentrations depending upon the bacterial susceptibility to the antibactehals being applied and the desired level of sterilization, sanitation, antisepsis, or disinfection.
  • the antibacterial compounds may be incorporated into a pharmaceutical composition.
  • certain antibactehals described herein may be useful for treating microbial infections in mammals, such as by administering an effective amount of the antibacterial compound to the mammal.
  • Embodiments of the present invention encompass any racemic, optically- active, polymorphic, tautomeric, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein.
  • compositions are sufficiently basic or acidic to form stable nontoxic acid or base salts
  • use of the compounds as pharmaceutically acceptable salts may be appropriate.
  • pharmaceutically acceptable salts within the scope of embodiments of the present invention include organic acid addition salts formed with acids which form a physiological acceptable anion and inorganic salts.
  • compositions in accordance with embodiments of the invention may be prepared by combining the disclosed compounds with a solid or liquid pharmaceutically acceptable carrier and, optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques.
  • Solid form compositions include powders, tablets, dispersible granules, capsules, cachets and suppositories.
  • a solid carrier may be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent.
  • Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the like.
  • Liquid form compositions include solutions, suspensions and emulsions.
  • solutions of the compounds of this invention dissolved in water and water-propylene glycol systems, optionally containing suitable conventional coloring agents, flavoring agents, stabilizers and thickening agents.
  • a pharmaceutical composition may be provided employing conventional techniques in unit dosage form containing effective or appropriate amounts of one or more active component.
  • the quantity of active component (compound) in a pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application, the potency of the particular compound and the desired concentration.
  • the quantity of active component may range from 0.5% to 90% by weight of the composition.
  • the compounds or pharmaceutical compositions thereof in therapeutic use for treating, or combating, bacterial infections in animals, may be administered oraliy, parenteraliy and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-ievel of active component in the animai undergoing treatment which is antibacteriaiiy effective,
  • a concentration that is, an amount, or blood-ievel of active component in the animai undergoing treatment which is antibacteriaiiy effective
  • such an antibacteriaiiy effective amount of dosage of active component may be in the range of about 0.1 to about 100 mg/kg. more preferably about 3.0 to about 50 mg/kg. of body weight/day.
  • ⁇ t is Io be understood that [he dosages may vary depending upon the requirements of the patient, the seventy of the bacterial infection being treated, and the particular compound being used.
  • the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., 2-4 four times per day.
  • an initial antibacterial compound was provided and tested. Such compound is identified below as compound A.
  • Compound A is identified below as compound A.
  • Compound A (below) is an inhibitor of gram positive bacteria. Compound A also shows activity against some strains of Entercoccus.
  • Compound A was broken down into smaller structural components and each fraction tested to understand the impact of certain components on the antibacterial properties of the compounds. Based on the understanding of compound A, the compounds (compounds 1 and 2) shown below, were tested further. Compounds 1 and 2 exhibit good activity (as measured by minimum inhibitory concentration testing) against several strains of Staphylococcus aureus and Entercoccus as shown in Figure 1.
  • a minimum inhibitory concentration is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation.
  • the exemplary compounds described above may be synthesized according to the following general procedures. Both compound 1 and compound 2 follow the same synthesis up to the formation of hydroxyamidine. As illustrated in Figure 2, initial coupling of commercially available starting materials of 4-iodobenzonitrile with either phenol or 4- thfluoromethyl phenol gave compounds 3a or 3b using standard Ullmann conditions. The purified product was then reacted with hydroxylamine to form the hydroxyamidine (compounds 4a or 4b) in quantative yield.
  • Thfluoromethyl hydroxyamidine (compound 4a) was coupled to 4- benzyloxybenzoylchloride using ethyldiisopropylamine to form the amidoxime intermediate (compound 5) in 58% yield (see Figure 3) and was ring closed to form the 1 ,2,4-oxadiazole (compound 6a) with tetrabutyl-ammonium fluoride. Standard deprotection of compound 6a with Pd/C produced compound 1. Synthesis of compound 2 was achieved by following standard EDC coupling to compound 4b and commercially available 4-benzyloxybenzoic acid and then ring closing in a one pot reaction to give 1 ,2,4-oxadiazole (compound 6b).
  • the organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 50 ml_). The organic layers were combined and washed with brine (100 ml_) and dried with Na2SO 4 and concentrated in vacuo. The crude liquid was placed on a silica gel column and purified CH 2 CI 2 /Hex (1 :8 ⁇ 1 :4) and then was recrystallized with hot hexane to give the product as white crystals (286 mg, 50 %).
  • Benzyl-O-4-fluorobenzamidoxime (compound 18 - structure shown below): A solution of (Z)-N'-hydroxybenzamidine (102 mg, 0.75 mmol) in methylene chloride (2.0 mL) and N-ethyldiisopropylamine (26 ⁇ L, 1.5 ⁇ mol) was cooled to 0 0 C in an iced-water bath under an atmosphere of nitrogen. Then 4- fluorobenzoyl chloride (13 ⁇ L, 1.1 mmol) was added dropwise and the mixture was stirred for 1 hour at 0 0 C. The solution was allowed to warm to room temperature and was then stirred for 19 hours.
  • Benzyl-O-4-bromobenzamidoxime (compound 20 - structure shown below): (Z)-N'-Hydroxybenzamidine (226, 1.66 mmol) was added methylene chloride (5.0 mL) and N-ethyldiisopropylamine (433 mg, 3.32 mmol). The solution was cooled to 0 0 C and placed under nitrogen. Then 4-bromobenzoyl chloride (372 mg, 1.66 mmol) was added dropwise and the mixture was stirred for 1 hour at 0 0 C. The solution was allowed to warm to room temperature and was then stirred for 48 hours.
  • the cooled mixture was partitioned between ethyl acetate (50 ml_) and water (50 ml_). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 50 ml_). The organic layers were combined and washed with brine (50 ml_) and dried with Na2SO 4 and concentrated in vacuo. The crude solid was placed on a silica gel column and purified (EtOAc/Hex 1 :8) to give the product as an off white solid (1.61 g, 87%).
  • 4-(pyridin-2-yloxy)benzonitrile (compound 41 - structure shown below): 4-Hydroxybenzonitrile (1.00 g, 8.39 mmol) was dissolved in anhydrous DMSO (5.0 mL) and was slowly added a solution of potassium tert-butoxide in THF (1.0 M, 16.8 mmol). The solution was stirred for 2 hours 30 minutes. A solution of 2-bromopyridine (2.65 g, 16.8 mmol) in DMSO (5.0 mL) was then added to the reaction mixture the whole was heated at 160 0 C for 115 hours. The cooled mixture was partitioned between ethyl acetate (100 mL) and water (100 mL).
  • Table 2 lists additional bacteria tested with compounds 1 and 2.
  • R O, N, NH, S or CH 2 .
  • One of ordinary skill in the invention would be aware of further analogues of the compounds of Figure 4 and the other compounds presented herein, and to the extent such analogues are encompassed by the claims as presented, such analogues are included herein.
  • Embodiments of the present invention also provide methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein.
  • compounds in accordance with embodiments of the present invention are designed to target penicillin-binding proteins.
  • compounds in accordance with embodiments of the present invention may be designed to target other biological process of bacteria.
  • a method for inhibiting growth of bacteria comprising providing a source containing bacteria, and contacting the source with at least one compound, such as the compounds provided herein, as well as other compounds individually or in combination.
  • a source may be a human or an animal and a contacting operation may be performed in vivo in said human or animal, or may be performed in vitro on an extracted sample or testing sample.
  • gram positive bacteria and, in particular the PBPs on gram positive bacteria, may be targeted for inhibition.
  • strains of Entercoccus and/or Staphylococcus aureus may be targeted.
  • other bacterial strains may be targeted, such as but not limited to M. tuberculosis, B. anthraces, or others.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des modes de réalisation de la présente invention portent sur de nouveaux antibactériens qui ciblent des protéines de liaison à la pénicilline ou d'autres cibles cellulaires importantes. L'invention porte également sur des procédés d'inhibition de la croissance (reproduction, etc.) de bactéries à l'aide des composés présentement décrits. Divers modes de réalisation présentent une activité à l'encontre des bactéries à gram positif, telles que certaines souches d'entérocoques et de staphylocoques dorés.
PCT/US2007/079672 2007-09-27 2007-09-27 Composés antibactériens et leurs procédés d'utilisation WO2009041972A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2007/079672 WO2009041972A1 (fr) 2007-09-27 2007-09-27 Composés antibactériens et leurs procédés d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/079672 WO2009041972A1 (fr) 2007-09-27 2007-09-27 Composés antibactériens et leurs procédés d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/680,541 Continuation-In-Part US7815868B1 (en) 2006-02-28 2007-02-28 Microfluidic reaction apparatus for high throughput screening

Publications (1)

Publication Number Publication Date
WO2009041972A1 true WO2009041972A1 (fr) 2009-04-02

Family

ID=40511733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/079672 WO2009041972A1 (fr) 2007-09-27 2007-09-27 Composés antibactériens et leurs procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2009041972A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013131872A1 (fr) * 2012-03-05 2013-09-12 Ge Healthcare Limited Activité neurale d'imagerie
US9040711B2 (en) 2012-07-02 2015-05-26 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
CN106866539A (zh) * 2017-03-06 2017-06-20 黑龙江八农垦大学 1‑取代苯基‑2‑烷基咪唑衍生物及其应用
EP3197888A4 (fr) * 2014-09-25 2018-03-14 University of Notre Dame du Lac Antibiotiques autres que les bêta-lactamines
EP2853532B1 (fr) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk Dérivés 1,2,4-oxadiazoliques comme modulateurs allostériques des récepteurs du glutamate métabotropique du groupe III
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007955A2 (fr) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Nouvelle utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007955A2 (fr) * 2001-07-20 2003-01-30 Cancer Research Technology Limited Nouvelle utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS ONLINE accession no. STN Database accession no. 2003:76617 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
WO2013131872A1 (fr) * 2012-03-05 2013-09-12 Ge Healthcare Limited Activité neurale d'imagerie
US9040711B2 (en) 2012-07-02 2015-05-26 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US9273037B2 (en) 2012-07-02 2016-03-01 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
EP2853532B1 (fr) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk Dérivés 1,2,4-oxadiazoliques comme modulateurs allostériques des récepteurs du glutamate métabotropique du groupe III
EP3197888A4 (fr) * 2014-09-25 2018-03-14 University of Notre Dame du Lac Antibiotiques autres que les bêta-lactamines
CN108463459A (zh) * 2014-09-25 2018-08-28 圣母大学 非β-内酰胺类抗生素
US10662164B2 (en) 2014-09-25 2020-05-26 University Of Notre Dame Du Lac Non-beta lactam antibiotics
US11168062B2 (en) 2016-09-12 2021-11-09 University Of Notre Dame Du Lac Compounds for the treatment of Clostridium difficile infection
CN106866539A (zh) * 2017-03-06 2017-06-20 黑龙江八农垦大学 1‑取代苯基‑2‑烷基咪唑衍生物及其应用

Similar Documents

Publication Publication Date Title
RU2414469C2 (ru) Новые производные оксазолидинона
JP5432890B2 (ja) 複素環誘導体及びその用途
JP5620020B2 (ja) 抗菌剤として有用なフルオロ−ピリジノン誘導体
JP6643773B2 (ja) 新規アルキレン誘導体
AU2011320665B2 (en) Cyclic amine substituted oxazolidinone CETP inhibitor
WO2009041972A1 (fr) Composés antibactériens et leurs procédés d'utilisation
TWI808305B (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
JP2016505055A (ja) Ｂａｃｅ１阻害剤としてのフルオロ−［１，３］オキサジン
JP2006500362A (ja) 置換ピロロピリジン類
SK282453B6 (sk) Fenyloxazolidinóny
NZ568904A (en) 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
SK7572002A3 (en) Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
WO2009082398A1 (fr) Composés antibactériens et leurs procédés d'utilisation
WO2012028629A1 (fr) 2-(benzyloxy) benzamides en tant qu'inhibiteurs de la lrrk2 kinase
EP2844656A1 (fr) Composés substitués de pyrazole en tant que modulateurs de crac
FR2514004A1 (fr) Antibiotiques de dioximino-cephalosporines
AU2018285449A1 (en) Benzofuran amides and heteroaromatic analogues thereof for use in therapy
JP2022542140A (ja) 阻害剤化合物
EP2163554B1 (fr) Dérivé de pyrimidodiazépinone
CA2515984A1 (fr) Indolone-oxazolidinones antibacteriens, intermediaires pour leur preparation et compositions pharmaceutiques les contenant
JP5100126B2 (ja) ピリミジニルイソオキサゾール誘導体
US20070004723A1 (en) Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
WO2007027878A2 (fr) Derives de 2-aryloxyphenol 4-substitues utilises comme agents antibacteriens
RU2662157C2 (ru) 2-пиридоновое соединение
JP2006522791A (ja) 抗微生物性［３．１．０］ビシクロヘキシルフェニルオキサゾリジノン誘導体および類似体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07843318

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07843318

Country of ref document: EP

Kind code of ref document: A1